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Abstract
Background: Psychodynamic psychotherapy is frequently applied in the treatment of social phobia. Nevertheless,
there has been a lack of studies on the transfer of manualized treatments to routine psychodynamic practice. Our study
is the first one to examine the effects of additional training in a manualized Short Term Psychodynamic Psychotherapy
(STPP) procedure on outcome in routine psychotherapy for social phobia. This study is an extension to a large multi-site
RCT (N = 512) comparing the efficacy of STPP to Cognitive-Behavioral Therapy (CBT) of Social Phobia.
Methods/Design: The manualized treatment is designed for a time limited approach with 25 individual sessions of
STPP over 6 months. Private practitioners will be randomized to training in manualized STPP vs. treatment as usual
without a specific training (control condition). We plan to enrol a total of 105 patients (84 completers).
Assessments will be conducted before treatment starts, after 8 and 15 weeks, after 25 treatment sessions, at the
end of treatment, 6 months and 12 months after termination of treatment. The primary outcome measure is the
Liebowitz Social Anxiety Scale. Remission from social phobia is defined scoring with 30 or less points on this scale.
Discussion: We will investigate how the treatment can be transferred from a controlled trial into the less
structured setting of routine clinical care. This question represents Phase IV of psychotherapy research. It combines
the benefits of randomized controlled and naturalistic research. The study is genuinely designed to promote faster
and more widespread dissemination of effective interventions. It will answer the questions whether manualized
STPP can be implemented into routine outpatient care, whether the new methods improve treatment courses and
outcomes and whether treatment effects reached in routine psychotherapeutic treatments are comparable to
those of the controlled, strictly manualized treatment of the main study.
Trial Registration: German Clinical Trials Register (DRKS) DRKS00000570
Background
Social phobia (SP, often also termed social anxiety disor-
der, SAD) is a disorder marked by an irrational intense
fear of social or performance situations in which embar-
rassment may occur. According to the DSM-IV [1] diag-
nostic criteria “exposure to the feared social situation
almost invariably provokes anxiety, which may take the
form of a situationally bound or situationally predisposed
panic attack” by concomitant discernment “that the fear
is excessive or unreasonable”. The symptoms must cause
clinically significant distress or impairment in social,
occupational, or other important areas of functioning.
The average 12 months prevalence rate of social phobia
in the German population is 2% [2,3]. Women are more
likely than males to develop a social phobia. Mean age of
onset is between age 10 and 16.6 years [4]. Social phobia
is a chronic disorder usually accompanied by comorbid
depression, personality disorders, other anxiety disorders
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any medium, provided the original work is properly cited.or substance abuse [4]. Keller (2003) indicates, that only
one-third of patients with social phobia attain full remis-
sion within 8 years [5]. Because the disorder is often mis-
taken as shyness, social phobia is often not recognized
and therefore undertreated [4,5].
The quality and effectiveness of psychodynamic psy-
chotherapy in clinical practice, conducted by more than
50% of certified psychotherapists [6] in Germany, is
unknown for patients with social phobia. As manualized
treatments for specific disorders have rarely been used in
psychodynamic training and practice, many psychodynamic
practitioners are likely to be biased against structured
short-term treatment approaches. The comparatively
recent diagnosis of social phobia has found little considera-
tion in psychodynamic research and practice. It is
unknown whether new treatment approaches such as
those evaluated in the first funding period of the Social
Phobia Network (Sopho-Net funded by the German
Federal Ministry of Education and Research, BMBF [7])
will improve the effects of routine psychodynamic psy-
chotherapy. Therefore it is important to investigate how
this new treatment method can be transferred from con-
trolled trials into the less structured setting of routine clini-
cal care, and whether the health care system benefits from
such developments. This question represents phase IV of
psychotherapy research.
Methods/Design
Study centres
The study is being carried outa tt h r e et r i a ls i t e s .T h e
participating centres are the Clinic for Psychosomatic
Medicine and Psychotherapy of the University Medial
Centre, Johannes Gutenber gU n i v e r s i t y ,M a i n z ,t h e
Department of Psychosomatics and Psychotherapy, Uni-
versity of Giessen and the Department of Psychosomatic
Medicine and Psychotherapy, Medical Faculty Carl Gus-
tav Carus, Technical University of Dresden.
In contrast to other RCTs in this trial patients are not
recruited by centres. Participating therapist announce
patients potentially fulfilling inclusion criteria and will-
ing to participate to the trial site.
For recruitment of therapists all officially listed (cham-
bers of psychotherapists and medical doctors) psychody-
namic psychotherapists in the regions of the trial sites
are asked for willingness to participate as study thera-
pists. All therapists underwent a specific training (about
5 years of training) in psychodynamic psychotherapy.
Due to the intended naturalistic character of our study
we have defined relatively broad inclusion criteria for
the participating therapists. Therapists can be of any age
and gender. Double certification in CBT is not an exclu-
sion criterion, as it is relatively rare in the German
health care system. Therapists from the first funding
period - specifically trained in STPP for Social Phobia
are excluded.
Therapeutic experience (including former training in
SET) and allegiance to the treatment condition will be
assessed.
Participants
Patients’ inclusion and exclusion criteria are listed in
table 1. According to these criteria, the sample of
patients included in the study is representative for
patients suffering from social phobia who qualify for
treatment in an outpatient setting. No subject will be
allowed to enrol in this trial more than once. Over a
period of three years, a total of 105 patients are planned
to be enrolled in the study (35 patients in each centre).
A minimum number of 84 completers is intended.
Interventions
The manualized treatment approach is based on Lubors-
ky’s Supportive Expressive Therapy (SET). The treat-
ment includes the characteristic elements of SET
therapy, that is, setting goals, focus on the Core Conflic-
tual Relationship Theme (CCRT) associated with the
patient’s symptoms, interpretive interventions to
enhance insight into the CCRT, and supportive inter-
ventions, in particular fostering a helping alliance. In
order to tailor the treatment more specifically to social
phobia, treatment elements have been added, for exam-
ple informing the patient about the disorder and the
treatment, a specific focus on shame and on unrealistic
demands, and encouraging the patient to confront anxi-
ety-provoking situations. More directive interventions
are included as well, such as specific prescriptions to
stop persisting self-devaluations [10]. The treatment is
designed for a time limited approach with 25 individual
sessions of STPP over 6 months (as reimbursed by
German health insurance).
Those patients who are treated in the control condi-
tion will receive standard psychodynamic treatment.
Assessment
The time points of assessment are shown in Figure 1.
Assessments will be conducted before treatment starts,
after 8 and 15 weeks, after 25 treatment sessions, at the
end of treatment, 6 months and 12 months after termi-
nation of treatment. If treatment exceeds 25 sessions
additional post-treatment assessment is performed
immediately after termination.
Patients are assessed by independent and trained SCID
interviewers, who are blind to the treatment condition.
Objectives and hypotheses
The research questions of this trial are:
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routine outpatient care?
(2) Will the new methods lead to an improvement of
treatment courses and outcomes?
(3) Will treatment effects reached in routine psy-
chotherapeutic treatments be comparable to those of
the controlled, strictly manualized treatment of the
main study?
The major hypotheses are: (1) Treatment effects
reached by private practitioners trained with the manua-
lized procedure of STPP of the main trial will be super-
ior to therapists who apply their usual psychodynamic
treatment. (2) Implementation of manualized STPP will
lead to an average reduction of treatment duration and
costs.
Further objectives: a) direct comparison (using the
same measures) of results based on an efficacy and an
effectiveness design; b) comparison between effective-
ness in different fields of health care delivery. In
combination with the results of the RCT from the first
funding period, this study will allow to estimate the
reduction of treatment duration and costs made possible
through implementation of treatment manuals derived
from the main trial into clinical practice.
Furthermore, this trial has been planned in close colla-
boration with the parallel trial for short-term cognitive-
behavioural therapy (CBT). Endpoints and outcome
measures were chosen in accordance with the main trial
[7] to allow comparisons between outcomes of the RCT
and the transfer studies included in this psychotherapy
research network. Outcome measures include interna-
tionally used valid and highly relevant measures of SP.
Outcomes
The primary outcome measure is the Liebowitz Social
Anxiety Scale (LSAS [9]) ≤30 indicating remission from
social phobia. The primary endpoint is the assessment
after 25 sessions. Secondary outcome measures include
Table 1 Inclusion and exclusion criteria
Inclusion
criteria
Diagnosis of SP (SCID-I [8]) and Liebowitz Social Anxiety Scale >30 (>60 for generalized subtype) [9]
age: 18 to 70 years
SP must be primary diagnosis (most severe disorder according to ADIS-IV)
SP patients with comorbid disorders will be included, provided that SP is the primary diagnosis, thus ensuring a clinically
representative sample as well as analyses of subgroups (e.g. type of SP, patients with comorbid depressive disorder)
Informed consent.
Exclusion
criteria
psychotic disorder
prominent risk of self-harm
acute substance related disorders
personality disorders except for cluster C: avoidant, obsessive-compulsive or dependent personality disorder (SCID-II)
organic mental disorder
severe medical conditions
concurrent psychotherapeutic treatment
psychopharmacological treatment (stable medical treatments; e.g. SSRI without dose adaptation are permitted)
Screening and 
Pre-treatment   Process    Post-treatment    Follow-up  (fu) 
T0a Pre-
screening by 
therapist 
T1 After 8 
weeks of 
treatment 
(postal) 
3) 4)
T3 After 25 sessions 
assessment (face to 
face) 
1) 3) 4) 5) 6) 7)
T5 6 month fu 
assessment 
(postal) 
3) 5) 6)
      
T0b Screening 
and pre-
treatment 
assessment (face 
to face) 
1) 2) 3) 5) 6) 
7)
T2 After 15 
weeks of 
treatment 
(postal) 
3) 4)
8) T4 post-
treatment 
assessment 
(postal) 
3) 4) 5)
T6 12 month fu 
assessment (face 
to face) 
1) 3) 5) 6) 7)
Figure 1 Time points of assessment.
1) SKID-Interview, CGI, LSAS-Interview,
2) Informed consent, check of inclusion criteria,
3) LSAS
questionnaire,
4) process measures (e.g. HAQ, patient self-rating of therapist’s adherence to treatment manual),
5) BDI,
6) EQ-5D, CSSRI,
7) SPAI,
FSKN, DKB-35, CDS, BSSS,
8) if treatment exceeds 25 sessions additional post-treatment assessment is performed immediately after termination.
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[11]) and scales for clinical global impression (CGI [12]),
depression (BDI [13]), self-image (FSKN [14]), body
image (DKB-35 [15]), depersonalization (CDS [16]),
social support (BSSS [17]), quality of life and social func-
tioning (EQ-5D [18]), Helping alliance (HAQ [19]), and
therapists treatment adherence judged by patients and
therapists. For this purpose self-rating scales for patients
and therapists based on J. Barber’s Penn Adherence
Competence Scale (PACS-SE [20]) were constructed. The
patient version has been applied in the first funding
phase of Sopho-Net.
Furthermore, costs of treatment of Social Phobia are
assessed with the German adaptation of the client socio-
demographic and service receipt inventory (CSSRI [21]).
This questionnaire includes information on health care
utilization and loss of productivity. All instruments will
be applied in both groups of this trial. Using established
cut-off scores for LSAS, the percentages of patients
defined as remitted will be assessed and statistically
compared between the group treated by specifically
trained therapists and the group receiving standard psy-
chodynamic treatment.
Sample size calculation
Being aware of the controversy whether RCT and efficacy
studies reach the same effect sizes we used two recent
meta-analyses on RCTs in STPP to estimate expected
effect sizes. Abbass et al. (2006) [22] included trials on
STPP with the majority of them (8 out of 13) not report-
ing manualized treatments. This condition comes closest
to our comparison group receiving standard psychody-
namic treatment. For general psychiatric symptoms effect
sizes were medium (short term outcome d = .42, long
term outcome d = .51). Based on the fact that effect sizes
for specific target problems are usually larger, both treat-
ment conditions will be expected to be superior to treat-
ment as usual or no treatment. Both treatments seem to
be highly acceptable and detrimental effects are not
expected.
In their meta-analysis, Leichsenring et al. (2004) [23]
reported effect sizes (prae-post) of d = .90 for the reduc-
tion of general psychiatric symptoms by STPP based on
strictly manualized treatments. Compared to the results
of Abbass et al. (2006) [22] with mostly non-manualized
STPP we expect the between group effect size to be
medium (about d = .48). Therefore, we pragmatically
expected an effect size of 0.50 between the two groups
(trained versus non trained therapist). In order to detect
this difference at alpha = .05 (one-tailed) with a power
of 0.80, N = 42 (one-tailed) patients per group are
required according to the formula of Campbell et al.
(2001) [24] for Cluster-Randomization, given that an
average of 2 patients per therapist will be treated:
N =2∗

σ(zα + zβ)
E
2
∗ [1 + (m − 1)ρ]=2∗

(zα + zβ)
ES
2
∗ [1 + (m − 1)ρ]
(za = z-value for probability of error type I alpha, zb =
z-value for probability of error type II beta, s = standard
deviation of outcome, E = expected ES of outcome, m =
mean observations for each cluster, r = Intracluster cor-
relation coefficient (ICC), ES = E/s = standardized effect
size)
While planning this study no meaningful published
data on remission rates for manualized vs. non-manua-
lized psychodynamic psychotherapy of social anxiety dis-
orders were available. We based sample size calculation
on available meta-analyses on psychodynamic psy-
chotherapy all based on continuous outcomes. Estimat-
ing the sample size needed for a dichotomous approach
(remission rates), we introduced the following conserva-
tive assumptions:
a) The ICC was set to 15%, which is high for comparable
studies. According to Campbell (2001) [24] the ICC for
outcome variables could be assumed to be less than 5%.
b) The average number of patients in a cluster was
assumed to be 2. In fact, due to the prevalence of the
disease we expect the average number of patients in a
cluster to be less than 2.
c) Within the planning the sample size of 42 per
group was calculated for patients completing the trial.
For the primary analysis (ITT) drop-outs will be ana-
lysed as patients without remission. When assuming less
than 50% remitters and an equal drop-out rate in both
treatment groups, the absolute difference between
remission rates will not change, but the relative differ-
ence will be much greater and will enlarge the difference
between treatments substantially.
At a conservative drop-out rate of 25% (taking into
account slightly elevated drop-outs in a practice study),
a total of N = 105 patients are required to be allocated
t ot h et r i a l .T h u s ,N=3 5p a t i e n t sw i l lh a v et ob e
included in each centre. According to the data of the
Davidson et al. (2004) [25] study with social phobia
patients, N = 257 patients would have to be assessed for
eligibility. As all patients have already received a clinical
diagnosis by the practitioner before undergoing the
standardized interview, we estimate that not more than
about 250 patients will have to be assessed for eligibility.
Randomization
Therapists will be randomly assigned either to a training
group in which they will undergo an intensive training of
the short-term STPP manual for social phobia as devel-
oped for the multi-centre study or to a control group in
which the non-manualized standard psychodynamic
treatment is applied. Randomization will be stratified tak-
ing into account the three trial sites. Randomization of
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before training of the therapists starts. Patients will not
be randomized and will not know whether their therapist
was recently trained in STPP for SP or not.
Statistical analysis
Primary analysis
The following hypothesis will be tested:
H0: πmanualized ≤ πstandard vs. H1: πmanualized > πstandard
where πmanualized and πstandard usual are the true remis-
sion probabilities in the manualized treatment group
and the standard routine care group after treatment per-
iod respectively.
Remission rates will be compared between specifically
trained STPP (manualized) and psychodynamic treatment
as usual (standard) group by logistic regression with cov-
ariates for treatment, sex of the therapist, and experience
of the therapist. Due to the cluster randomized nature of
the study a term for the therapist will be added. Within
each therapist compound symmetry will be assumed.
Intent-to-treat analyses (LOCF) as well as completer ana-
lyses will be conducted. Drop-outs will be considered as
non-responders/non-remitters in the analysis. As sensitiv-
ity analyses a chi-square test and a conditional logistic
regression adjusted for the therapist will be performed.
Also the LSAS will be analysed as a continuous measure
by means of mixed model with repeated measurements
for the ITT population. Replacement strategies of missing
values will be discussed after assessing the pattern of the
missing value structure.
Secondary analyses
Self-report questionnaires and observer ratings (SPAI,
CGI, BDI, FSKN, DKB-35, CDS, BSSS, EQ-5D, HAQ,
treatment adherence) will be analysed by mixed models
with repeated measurements. Further analyses will
include
￿ cross-sectional analyses comparing therapists;
￿ subgroup analyses of subjects’ and therapists’
conditions
￿ costs of the SP treatment (CSSRI)
All analyses will be conducted on a one-sided level of
significance of 0.05. Descriptive statistics showing the
measurements over time will be presented whenever
appropriate.
Serious adverse events and drop-outs will be analysed
descriptively.
Safety aspects
Safety parameters will comprise newly occurring psy-
chiatric diagnoses (SCID-I) and all serious adverse
events that are reported during and up to six months
after treatment.
Medical Complications
The recording of adverse events will be restricted to psy-
chological conditions. Formally, they are defined as any
disorder classified by the International Classification of
Diseases F00-F99 ("Mental and Behavioral Disorders”).
A serious adverse event (SAE) is an adverse event that
may occur at any time of the treatment phase or up to 6
months after end of treatment: results in death; is life-
threatening; requires subject hospitalization or prolonga-
tion of existing hospitalization; results in persistent or sig-
nificant disability/incapacity; is a congenital anomaly/birth
defect
Changes in mental disorders according to ICD-10 F00-
F99 will be specifically asked for in the CRF pages filled by
the interviewer at the following time-points: after 25 ses-
sion of treatment; twelve months after end of treatment.
Any AE (according to the study specific definition)
reported by the subject or detected by the local investiga-
tor will be collected during the trial and must be docu-
mented in the CRF. ICD-10 will be used by the local
investigator to code the event. The standard coding system
for adverse events, MedDRA, has been reported to be
inadequate in psychotherapeutic studies [26]. The clinical
course of the AE will be followed until it has changed to a
stable condition or until end of follow-up phase, whatever
comes first.
In case of SAEs Ethics Committee (EC) and Data
Safety Monitoring Board (DMSB) will be informed
within 24 hours after the SAE becomes known.
Ethical issues
T h ef i n a ls t u d yp r o t o c o la n dt h ef i n a lv e r s i o no ft h e
written informed consent form were approved by the
Ethics Committee of the Federal State of Rhineland
Palatine (Germany), which is responsible for the Princi-
pal Investigator (Ref. No. 037.249.10 [7258]).
The procedure set out in this protocol, pertaining to
the conduct, evaluation, and documentation of this trial,
were designed to ensure that all persons involved in the
trial abide by Good Clinical Practice (GCP) and the ethi-
cal principles described in the current revision of the
Declaration of Helsinki. The trial will be carried out in
keeping with local legal and regulatory requirements.
Before being admitted to the clinical trial, patients
must consent to participate after the nature, scope, and
possible consequences of the clinical trial have been
explained in a form understandable to them. The
patients must give written informed consent to partici-
pate in the study including their consent to publish.
Discussion
The study is designed as an extension to the larger multi-
site project in which Cognitive-Behavioral Therapy
(CBT) and Short Term Psychodynamic Psychotherapy
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ated [7]. It combines the benefits of randomized con-
trolled trials and naturalistic studies. We will ascertain to
what degree practitioners integrate the new methods into
their clinical routine. Furthermore, the study will deter-
mine whether the new methods lead to an improvement
of treatment course and outcome and also whether the
treatment effects of manualized STPP in routine psy-
chotherapeutic treatment are comparable to those of the
controlled, strictly manualized treatments of the main
study. This study estimates potential reductions of treat-
ment duration and costs by implementation of treatment
manuals into clinical practice.
In contrast to the previous RCT in this study the
patients are not recruited by the participating centres.
Patients will seek treatment in the regular way of the
German health care system attending private practi-
tioners. Therefore, participating therapists recruit
patients and announce them to the study centres. In the
previous RCT treatments were limited to 25 sessions. In
our study therapists are completely free to determine
treatment duration. Accordingly, we determined primary
outcome after 25 sessions. Our comparison group is
naturalistically treated with standard psychodynamic
psychotherapy without any additional training of the
therapists.
Examinations of these issues in a methodologically rig-
orous manner will be of high relevance not only for the
domain of social phobia but for the dissemination of
innovative psychotherapeutic treatments in general.
Implementing the best obtainable treatment into the
practice of experienced psychotherapists can be expected
to increase treatment effectiveness. While evidence for
the efficacy of Supportive Expressive Psychotherapy
(SET) and other variants of Short Term Psychodynamic
Psychotherapy (STPP) has accumulated [22,23], there has
been a lack of studies on the transfer of manualized treat-
ments to routine psychodynamic practice. Our study will
be the first one to directly examine the effects of an addi-
tional training in a manualized and highly effective STPP
procedure on outcome in routine psychotherapy for
social phobia.
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